Evidence map›Paper›PMID 29750813›Full record

ArticlePloS one2018

Autophagy mediates tumor necrosis factor-α-induced phenotype switching in vascular smooth muscle A7r5 cell line.

Marina García-Miguel, Jaime A Riquelme, Ignacio Norambuena-Soto, Pablo E Morales, Fernanda Sanhueza-Olivares, Constanza Nuñez-Soto, David Mondaca-Ruff, Nicole Cancino-Arenas, Alejandra San Martín, Mario Chiong

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Role of Vascular Smooth Muscle Cell Phenotype Switching in Arteriogenesis.International journal of molecular sciences · 2021
    Review
  15. Review
  16. Article
  17. Role of Interleukin-6 in Vascular Health and Disease.Frontiers in molecular biosciences · 2021
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Marina García-MiguelAdvanced Center for Chronic Disease (ACCDiS), Center for studies of Exercise, Metabolism and Cancer (CEMC), Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile.
Jaime A RiquelmeAdvanced Center for Chronic Disease (ACCDiS), Center for studies of Exercise, Metabolism and Cancer (CEMC), Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile.
Ignacio Norambuena-SotoAdvanced Center for Chronic Disease (ACCDiS), Center for studies of Exercise, Metabolism and Cancer (CEMC), Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile.
Pablo E MoralesAdvanced Center for Chronic Disease (ACCDiS), Center for studies of Exercise, Metabolism and Cancer (CEMC), Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile.
Fernanda Sanhueza-OlivaresAdvanced Center for Chronic Disease (ACCDiS), Center for studies of Exercise, Metabolism and Cancer (CEMC), Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile.
Constanza Nuñez-SotoAdvanced Center for Chronic Disease (ACCDiS), Center for studies of Exercise, Metabolism and Cancer (CEMC), Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile.
David Mondaca-RuffAdvanced Center for Chronic Disease (ACCDiS), Center for studies of Exercise, Metabolism and Cancer (CEMC), Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile.
Nicole Cancino-ArenasAdvanced Center for Chronic Disease (ACCDiS), Center for studies of Exercise, Metabolism and Cancer (CEMC), Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile.
Alejandra San MartínDivision of Cardiology, Department of Medicine, Emory University, Atlanta, Georgia, United States of America.
Mario ChiongAdvanced Center for Chronic Disease (ACCDiS), Center for studies of Exercise, Metabolism and Cancer (CEMC), Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile.ORCID 0000-0002-5174-6545
Advanced Center for Chronic Diseases · CLEmory University · US

Funding

T cell triggering events and hypertensionP01HL095070 · NHLBI · EMORY UNIVERSITY · PI JO, HANJOONG · 2009 to 2019
$20.5M
Mechanically Stressed VSMC: A Role for Slingshot Phosphatase in InflammationR01HL113167 · NHLBI · EMORY UNIVERSITY · PI SAN MARTIN, ALEJANDRA · 2013 to 2017
$1.9M
NHLBI NIH HHS P01 HL095070NHLBI NIH HHS R01 HL113167NIH HHS HL095070NIH HHS HL113167
6 · The paper itself

Abstract

Vascular smooth muscle cells (VSMC) dedifferentiation from a contractile to a synthetic phenotype contributes to atherosclerosis. Atherosclerotic tissue has a chronic inflammatory component with high levels of tumor necrosis factor-α (TNF-α). VSMC of atheromatous plaques have increased autophagy, a mechanism responsible for protein and intracellular organelle degradation. The aim of this study was to evaluate whether TNF-α induces phenotype switching of VSMCs and whether this effect depends on autophagy. Rat aortic Vascular smooth A7r5 cell line was used as a model to examine the phenotype switching and autophagy. These cells were stimulated with TNF-α 100 ng/mL. Autophagy was determined by measuring LC3-II and p62 protein levels. Autophagy was inhibited using chloroquine and siRNA Beclin1. Cell dedifferentiation was evaluated by measuring the expression of contractile proteins α-SMA and SM22, extracellular matrix protein osteopontin and type I collagen levels. Cell proliferation was measured by [3H]-thymidine incorporation and MTT assay, and migration was evaluated by wound healing and transwell assays. Expression of IL-1β, IL-6 and IL-10 was assessed by ELISA. TNF-α induced autophagy as determined by increased LC3-II (1.91±0.21, p<0.001) and decreased p62 (0.86±0.02, p<0.05) when compared to control. Additionally, TNF-α decreased α-SMA (0.74±0.12, p<0.05) and SM22 (0.54±0.01, p<0.01) protein levels. Consequently, TNF-α induced migration (1.25±0.05, p<0.05), proliferation (2.33±0.24, p<0.05), and the secretion of IL-6 (258±53, p<0.01), type I collagen (3.09±0.85, p<0.01) and osteopontin (2.32±0.46, p<0.01). Inhibition of autophagy prevented all the TNF-α-induced phenotypic changes. TNF-α induces phenotype switching in A7r5 cell line by a mechanism that required autophagy. Therefore, autophagy may be a potential therapeutic target for the treatment of atherosclerosis.

Indexed as

AutophagyAnimalsAtherosclerosisCell LineInterleukin-10Interleukin-1betaInterleukin-6Muscle, Smooth, VascularMyocytes, Smooth MuscleRatsTumor Necrosis Factor-alphaIL1B protein, ratInterleukin-10Interleukin-1betaInterleukin-6Tumor Necrosis Factor-alpha

Identifiers

PMID29750813
PMCPMC5947899
OpenAlexW2800521804

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.